Saturday, July 15, 2023 10:13:06 AM
Ilovetech,
Yes, by 2014 big pharma well understood the threat of DCVax from their own research indicating that it made their treatments more effective. That meant that if L passed muster on its own NWBO could be in the driver’s seat. Well that day has come and NWBO survived the attacks in the interim.
Now the effort is being made to get shareholders separated from their shares while still well undervalued between now and some time after an initial approval. Big pharma will likely try to use this time try and buy cheap but there will be competition for how to move forward and collusion to divide the spoils would likely fall apart quickly as not all pharmas are “controlled” by the “enlightened ones” and their supporters.
Big supporters of NWBO currently need to be aware of this as do retail investors who will be the target and may even be led to believe that a long time vocal supporter is really on their side when they try to use influence to move in a direction different than that of what may be best for the long term vision for extracting value from this platform. Short term vs long term financial goals is always up for debate so shareholders will likely be put to the test at some point in the fairly early stages of post approval development. Seems like the first indications of this have already been publicly shared. Best wishes.
Yes, by 2014 big pharma well understood the threat of DCVax from their own research indicating that it made their treatments more effective. That meant that if L passed muster on its own NWBO could be in the driver’s seat. Well that day has come and NWBO survived the attacks in the interim.
Now the effort is being made to get shareholders separated from their shares while still well undervalued between now and some time after an initial approval. Big pharma will likely try to use this time try and buy cheap but there will be competition for how to move forward and collusion to divide the spoils would likely fall apart quickly as not all pharmas are “controlled” by the “enlightened ones” and their supporters.
Big supporters of NWBO currently need to be aware of this as do retail investors who will be the target and may even be led to believe that a long time vocal supporter is really on their side when they try to use influence to move in a direction different than that of what may be best for the long term vision for extracting value from this platform. Short term vs long term financial goals is always up for debate so shareholders will likely be put to the test at some point in the fairly early stages of post approval development. Seems like the first indications of this have already been publicly shared. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
